LogicBio-logo-RGB.png
LogicBio Therapeutics Receives FDA Orphan Drug Designation for LB-001 for the Treatment of Methylmalonic Acidemia
29 avr. 2019 08h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
logic_bio_new.jpg
LogicBio Therapeutics Expands Leadership Team and Bolsters Capabilities to Support GeneRide™ Platform Development and Advancement of Lead Program into Clinic
22 avr. 2019 08h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
logic_bio_new.jpg
LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
01 avr. 2019 08h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
logic_bio_new.jpg
LogicBio Therapeutics to Present at Upcoming March Conferences
25 févr. 2019 07h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc.  (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
logic_bio_new.jpg
LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development
22 févr. 2019 07h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
logic_bio_new.jpg
LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors
06 déc. 2018 08h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc.  (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
logic_bio_new.jpg
LogicBio Reports Third Quarter 2018 Financial Results
03 déc. 2018 08h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat...
logic_bio_new.jpg
LogicBio Announces Partnership with Children’s Medical Research Institute to Develop Next Generation Viral Vectors
15 nov. 2018 06h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., Nov. 15, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ: LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today...
logic_bio_new.jpg
LogicBio to Present at the Jefferies 2018 London Healthcare Conference
13 nov. 2018 08h00 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients...
logic_bio_new.jpg
LogicBio Therapeutics Announces Closing of Initial Public Offering
23 oct. 2018 16h05 HE | LogicBio Therapeutics
CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients...